Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference
06 mars 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
05 mars 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
15 févr. 2018 11h00 HE
|
Kura Oncology, Inc.
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – –...
Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
08 févr. 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Added to Nasdaq Biotechnology Index
18 déc. 2017 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
11 déc. 2017 10h00 HE
|
Kura Oncology, Inc.
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of...
Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
10 déc. 2017 09h00 HE
|
Kura Oncology, Inc.
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine...
Kura Oncology to Host Investor Day on November 16, 2017
09 nov. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
07 nov. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
01 nov. 2017 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...